Skip to content
Peptide Atlas
All peptides

BPC-157

Tier 2 · Preclinical
Also known as BPC157 · Body Protection Compound 157 · Bepecin

The strongest evidence present is Tier 1 human data, but it is minimal: only three small pilot studies (a retrospective intra-articular knee-pain chart review of up to 16 patients per src-19/src-18, an intravesical interstitial cystitis study of 12 women per src-30, and an intravenous safety/PK study of just 2 healthy adults per src-28). Multiple reviews (src-3, src-6, src-16, src-18, src-21) and a 2025 systematic review (src-9) agree that BPC-157's benefits are demonstrated mainly in preclinical (mostly small rodent) and in vitro models, with zero completed controlled human efficacy trials. Human efficacy figures each derive from single, small, uncontrolled studies, and src-21 notes the knee case series had significant methodological flaws and no controls.

Half-life
~0.5 h
Routes
Subcutaneous · Intramuscular · Intraperitoneal · Intravenous · Intragastric · Oral (in drinking water) · Topical · Local injection (e.g. intra-articular, intravesical)
Goals
Injury recovery and tissue repair · Gastrointestinal protection · Tendon/ligament healing · Athletic recovery
Cost / mg
$18

How it works

Several reviews describe BPC-157 as a synthetic 15-amino-acid peptide originally isolated from human gastric juice (src-1, src-3, src-6). Animal and in vitro studies report it promotes the growth of new blood vessels, helps cells migrate to repair tissue, and protects tissues from damage. Studies attribute these effects to its interaction with nitric oxide production and growth-factor signaling, and reviews report it appears especially effective in poorly-vascularized tissues such as tendons and ligaments (src-3, src-4, src-6). Almost all of this evidence is preclinical; human data are minimal.

Overview

Overview

Several reviews describe BPC-157 (also called Body Protection Compound 157 or Bepecin) as a synthetic pentadecapeptide of 15 amino acids, originally isolated from human gastric juice (src-1, src-3, src-6, src-17, src-23, src-27). Sources report the sequence as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), a 15-residue chain with a triple-proline stretch and a molecular weight of approximately 1419 Da (src-8, src-11, src-14); this triple-proline 15-mer is the form consistent with both the pentadecapeptide descriptor and the 1419 Da weight, and it is said to give exceptional stability and resistance to digestive enzymes (src-11). One pharmacokinetic paper prints a quadruple-proline (16-residue) version while still stating the peptide has 15 amino acids and a weight of 1419 Da, which appears to be a transcription error, since a fourth proline would add roughly 97 Da (src-4). Sources describe it as derived from a partial sequence of a larger ~40,000-dalton Body Protection Compound protein present in human gastric juice (src-8, src-9, src-11), and one source notes it is not a naturally occurring bioactive peptide in the conventional sense (src-9). Sources state it was first isolated and characterized in 1993–1994 by Dr. Predrag Sikirić, Seiwerth and colleagues at the University of Zagreb, Croatia, who identified its cytoprotective properties in animal models of gastric ulceration (src-8, src-9, src-11, src-12).

Reported effects

Reviews report BPC-157 demonstrated pleiotropic beneficial effects across numerous preclinical (mostly small rodent) models of tissue injury, inflammatory bowel disease and CNS disorders (src-1, src-6, src-16, src-17). Animal studies report it promotes healing of wounds, tendon and ligament injuries, muscle injuries, fractures/bone, nerves, spinal cord, cornea and blood vessels (src-4, src-6, src-18, src-20, src-25), and reviews report protective effects across esophagus, stomach, duodenum, colorectal mucosa, liver, pancreas, muscle, cornea, heart and nerves (src-3, src-4, src-6, src-23). Reviews report its effects appear particularly effective in poorly vascularized tissues such as tendons and myotendinous junctions (src-3, src-4, src-6, src-23). An animal study reports it accelerated healing of a transected rat Achilles tendon (src-27), and a review reports rats with limb damage showed more blood vessels after a week of treatment versus control (src-14). An animal review also reports it may be hepatoprotective, may aid recovery from traumatic brain injury and may influence blood clot formation/degradation (src-12). One review reports that, unlike bFGF, EGF and VEGF, it showed consistent effectiveness across both GI and extra-GI tissues (src-25).

Evidence base

Sources state BPC-157 has been investigated in over 100 preclinical studies (one vendor citing over 130 papers across three decades), while two systematic reviews published in 2025 confirmed a large gap between preclinical promise and clinical evidence (src-8, src-11). A systematic review identified 544 articles from 1993 to 2024 and included 36 studies (35 preclinical and 1 clinical), reporting improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bony injuries in preclinical models (src-18). One guide characterizes the evidence base as 35 preclinical animal studies and a single uncontrolled 16-patient chart review, with a 2025 systematic review documenting zero completed controlled human efficacy trials (src-9).

Reviews report that only three small pilot studies have examined BPC-157 in humans — for intra-articular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics — with no adverse effects reported, but state rigorous, large-scale human trials are lacking (src-3, src-6, src-8, src-23). A 2019–2020 retrospective chart review reported that among patients receiving intra-articular BPC-157 alone, 11 of 12 (91.6%) had significant knee pain improvement; overall 14 of 16 patients (87.5%) had relief with 6-month to 1-year follow-up (src-19); the study authors suggest it has potential to repair tears, build cartilage, reduce the number of knee surgeries and offer advantages over steroids (src-19). A review reports 7 of 12 patients in a retrospective intra-articular knee-pain study had relief for more than 6 months (src-18), but another review notes this case series had significant methodological flaws and lacked controls, limiting reliability (src-21). A study of intravesical BPC-157 in 12 women with moderate-to-severe interstitial cystitis unresponsive to pentosan polysulfate reported complete symptom resolution after one 10 mg treatment in 10 of 12, all 12 scoring 5/5 on the Global Response Assessment, with no adverse events (src-30). An intravenous study in 2 healthy adults reported that infusions of 10 mg and up to 20 mg over one hour produced no measurable effects on biomarkers and were well tolerated (src-28). One guide states Phase 1 human trials are described as underway by the originating research group, but no completed human efficacy trials had been published as of April 2026 (src-9, src-10).

Pharmacokinetics

Animal pharmacokinetic studies report an elimination half-life under 30 minutes in rats and beagle dogs with linear pharmacokinetics (src-4, src-15, src-18), mean absolute bioavailability after IM injection of approximately 14–19% in rats and 45–51% in beagle dogs (src-4, src-15), and excretion via urine and bile with rapid metabolism into small peptide fragments and amino acids (src-4, src-15, src-18). Sources report it is freely soluble in water at normal pH, can be stored at room temperature, and is resistant to hydrolysis and gastric juice, remaining stable in gastric juice for over 24 hours (src-4, src-8, src-11, src-14). An ex vivo review reports 36% of intact BPC-157 remained after 60 minutes in plasma (src-14). A review states the effects of orally ingested BPC-157 are currently unknown (src-14), and a theoretical review estimates a short serum half-life with sustained downstream effects via VEGFR2 and FAK-paxillin cascades (src-10).

Regulatory status

Sources report BPC-157 has not received regulatory approval in any jurisdiction, was banned by WADA in 2022 (under S0 Unapproved Substances; one review notes it was later not listed as banned), and has been classified by the FDA as a 503A Category 2 bulk drug substance since September 2023, barring inclusion in compounded medications (src-8, src-9, src-12, src-13, src-17, src-18). One guide states it cannot be legally obtained through a licensed U.S. compounding pharmacy and has no FDA-approved indication (src-9). A review notes it is unregulated, readily available for purchase over the internet, and marketed as an unapproved peptide compound directly to patients (src-24, src-26).

What the research shows

248 findings extracted from the 30 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 2 human trial findings, 14 human study findings, 24 animal findings, 17 expert opinion findings and 2 anecdotal findings.

  • human trialComplete resolution of symptoms after one treatment was reported in 10 of 12 patients5

  • human trialAll 12 patients scored a 5/5 on the Global Response Assessment5

  • human studyOnly three pilot studies have examined BPC-157 in humans, including its use for intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics1

  • human studyHuman research remains limited to small pilot studies investigating musculoskeletal pain, interstitial cystitis, and intravenous administration2

  • human studyBPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials3

  • human studyA single human case series reported improvements in pain after intra-articular knee injections of BPC-157, although significant methodological flaws and a lack of controls limit its applicability and reliability3

  • human studyOnly three pilot studies have examined BPC-157 in humans, including its use for intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics9

  • human studyIn a retrospective study of musculoskeletal pain following intraarticular injection of BPC-157 for unspecified chronic knee pain, 7 of 12 patients reported relief for >6 months11

Show the remaining 51

  • human studyOnly three pilot studies have examined BPC-157 in humans, including its use for intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics13

  • human studyThe only human study found was small and inconclusive22

  • human studyThree small pilot studies have been published: a retrospective study of intra-articular injection for knee pain (2021), an intravesical injection study for interstitial cystitis (2024), and an intravenous safety study (2025)23

  • human study11 of 12 patients (91.6%) receiving intra-articular BPC-157 injection alone had significant improvement in knee pain26

  • human study1 of 12 patients (8.3%) receiving BPC-157 alone had no improvement in knee pain26

  • human study75% of patients receiving combination of BPC-157 and TB4 showed significant improvement in knee pain26

  • human study25% of patients receiving combination of BPC-157 and TB4 had no relief of knee pain26

  • human studyOverall 14 of 16 patients (87.5%) had relief of knee pain when BPC-157 or combination of BPC-157 and TB4 was used26

  • animalBPC-157 has demonstrated regenerative properties across numerous animal models1

  • animalBPC-157 has demonstrated regenerative properties in animal models for tendons, ligaments, muscles, nerves, bones, teeth, corneas, and the endothelium1

  • animalBPC-157 has demonstrated notable reparative and anti-inflammatory properties across diverse preclinical models2

  • animalBPC-157 shows high efficacy for rats suffering toxic or surgical trauma7

  • animalRats given limb damage showed more blood vessels in the damaged limb after a week of BPC-157 treatment compared to control7

  • animalBPC-157 has demonstrated regenerative properties across numerous animal models9

  • animalBPC 157 demonstrated pleiotropic beneficial effects in various preclinical models mimicking medical conditions, such as tissue injury, inflammatory bowel disease, or CNS disorders10

  • animalPreclinical studies show its potential for promoting healing in musculoskeletal injuries such as fractures, tendon ruptures, ligament tears, and muscle injuries11

  • animalIn preclinical models, BPC-157 improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bony injuries11

  • animalBPC-157 demonstrated pleiotropic beneficial effects in various preclinical models mimicking medical conditions such as tissue injury, inflammatory bowel disease, or CNS disorders12

  • animalBPC-157 has demonstrated regenerative properties across numerous animal models13

  • animalBPC-157 demonstrates robust regenerative and cytoprotective effects in preclinical studies13

  • animalBPC-157 simultaneously cures cutaneous and other tissue wounds (colocutaneous, gastrocutaneous, esophagocutaneous, duodenocutaneous, vesicovaginal, and rectovaginal) in rats15

  • animalBPC-157 is effective in counteracting bleeding disorders produced by amputation and/or anticoagulants application15

  • animalBPC-157 may prevent and/or attenuate or eliminate arterial and venous thrombosis15

  • animalBPC 157 demonstrates consistently positive and prompt healing effects for various injury types, both traumatic and systemic and for a plethora of soft tissues16

  • animalSkeletal muscle injury models have suggested a beneficial effect not only for disturbances that occur as a result of direct trauma but also for systemic insults including hyperkalemia and hypermagnesemia16

  • animalBPC 157 was consistently effective in all models of acute/chronic injury of esophagus, stomach, duodenum and lower gastrointestinal tract17

  • animalBPC 157 improves tendon, ligament and bone healing using same regimens as in gastrointestinal healing studies17

  • animalUnlike bFGF, EGF, and VEGF, BPC 157 shows consistent effectiveness across both gastrointestinal and extragastrointestinal tissue healing models17

  • animalBPC 157 has been experimentally demonstrated to accelerate the healing of many different wounds, including transected rat Achilles tendon19

  • animalBPC 157 holds potential in tissue regeneration, improving blood flow, and reducing inflammation, as demonstrated in animal studies22

  • animalBPC-157 was first described and characterized in the early 1990s by Predrag Sikiric and colleagues at the University of Zagreb, Croatia, who identified its potent cytoprotective properties in animal models of gastric ulceration23

  • animalBPC-157 demonstrates favorable tissue repair outcomes in animal models24

  • expert opinionBPC-157 has limited clinical validation2

  • expert opinionThere is currently little evidence that it provides benefits for people7

  • expert opinionThere is a current lack of clinical trials for therapeutic peptides including BPC-1578

  • expert opinionBPC-157 has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans12

  • expert opinionThe efficacy of BPC 157 is yet to be confirmed in humans16

  • expert opinionBPC 157 is the most potent angiomodulatory agent18

  • expert opinionBPC-157 has accumulated over 130 published research papers spanning three decades with studies demonstrating consistent healing effects across tendons, ligaments, muscles, gastrointestinal tract, and nerve tissue20

  • expert opinionEvidence base of 35 preclinical animal studies and a single uncontrolled 16-patient chart review21

  • expert opinionPhase 1 human trials are described as underway by the originating research group, but no completed human efficacy trials have been published as of April 202621

  • expert opinion2025 systematic review documented zero completed controlled human efficacy trials21

  • expert opinionBPC-157 has been investigated in over 100 preclinical studies23

  • expert opinionTwo systematic reviews published in 2025 confirmed the large gap between preclinical promise and clinical evidence23

  • expert opinionBody protection compound 157 (BPC-157) is at the forefront of therapeutic peptides, with early demonstrations of this experimental peptide optimizing endurance training, metabolism, recovery, and tissue repair25

  • expert opinionThere is scarce orthopaedic literature investigating the clinical use and outcomes of therapeutic peptides like BPC-157 in tendon, muscle, and cartilage injury25

  • expert opinionBPC-157 has potential to repair tears, build cartilage and reduce number of knee surgeries26

  • expert opinionBPC-157 reparative properties offer advantages over use of steroids26

  • expert opinionNo completed Phase 1-3 clinical trials for BPC-157 have been published27

  • anecdotalMost users notice initial improvements within 3 to 7 days, with optimal benefits appearing over 4 to 8 weeks of consistent use20

  • anecdotalUser experienced shoulder pain improvement from 7/10 to 2-3/10 over 6 weeks at 0.25 mg twice daily subcutaneous injection20

How it works

Based on 31 animal findings, 19 in vitro findings, 18 expert opinion findings and 9 theoretical findings.

  • animalBPC-157 activates VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis1

  • animalBPC-157 promotes angiogenesis, fibroblast activity, and neuromuscular stabilization1

  • animalBPC-157 engages ERK1/2 signaling, facilitates endothelial and muscle repair1

  • animalBPC-157 exerts anti-inflammatory effects1

  • animalBPC-157 may influence blood clot formation/degradation1

  • animalExperimental evidence reveals that BPC-157 supports angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways2

  • animalBPC-157 reduces inflammatory cytokine activity2

  • animalBPC-157 improves microvascular integrity2

Show the remaining 69

  • animalBPC-157 has beneficial effects on pain modulation through peripheral and dopaminergic mechanisms2

  • animalBody-protective compound (BPC) 157 demonstrates protective effects against damage to various organs and tissues6

  • animalBPC-157 activates VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis9

  • animalBPC-157 promotes angiogenesis, fibroblast activity, and neuromuscular stabilization9

  • animalBPC-157 engages ERK1/2 signaling9

  • animalBPC-157 facilitates endothelial and muscle repair9

  • animalBPC-157 exerts anti-inflammatory effects9

  • animalBPC 157 has a modulatory effect on dopamine level, as it antagonizes catalepsy induced by dopamine antagonist haloperidol10

  • animalBPC 157 mitigates harmful effects caused by amphetamine10

  • animalBPC-157 enhances growth hormone receptor expression and several pathways involved in cell growth and angiogenesis, while reducing inflammatory cytokines11

  • animalBPC-157 activates VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilization13

  • animalBPC-157 engages ERK1/2 signaling, facilitates endothelial and muscle repair, and exerts anti-inflammatory effects13

  • animalBPC-157 promotes angiogenesis, fibroblast activity, and neuromuscular stabilization, particularly in poorly vascularized tissues such as tendons and myotendinous junctions13

  • animalBPC157 is a peptide isolated from human gastric juice14

  • animalBPC157 has demonstrated cytoprotective and anti-inflammatory properties and plays a role in maintaining epithelial integrity14

  • animalBPC157 has demonstrated significant effects at very low doses with very good stability14

  • animalHealing of wounds by BPC-157 is accomplished by resolution of vessel constriction, the primary platelet plug, the fibrin mesh, and resolution of the clot15

  • animalBPC-157 has particular action in ischemia/reperfusion by circumventing occluded vessels15

  • animalBPC-157 rapidly increases various genes expression in rat excision skin wound15

  • animalBPC 157 implements its own angiogenic effect in healing17

  • animalPreclinical evidence suggests BPC-157 activates the VEGFR2-Akt-eNOS signaling pathway, modulates nitric oxide production, and engages the FAK-paxillin pathway in tendon fibroblasts21

  • animal2020 study used isolated rat aorta to show concentration-dependent, endothelium-dependent vasodilatory effect21

  • animalBPC-157 modulates dopamine and serotonin turnover23

  • in vitroBPC-157 increased angiogenesis by 129+/-7% and 152+/-14% in CAM assay at doses of 0.01 μg and 0.1 μg respectively7

  • in vitroConcentrations of 0.1 μg/mL and 1 μg/mL increased tube formation by 119+/-9% and 147+/-7% over 24 hours in HUVECs7

  • in vitroBPC-157 activates VEGFR2 protein and internalizes it within a cell to activate the VEGFR2-Akt-eNOS pathway7

  • in vitroBPC-157 stimulates mRNA of growth factor EGR-1 in intestinal cells (Caco-2) at 10-100 μM, with most efficacy at 50 μM7

  • in vitroBPC 157 positively interacts with nitric oxide synthase to increase expression of several antioxidants, including heme oxygenase (HO-1)10

  • in vitroBPC 157 may stimulate VEGF receptors10

  • in vitroBPC 157 significantly accelerated the outgrowth of tendon explants19

  • in vitroCell proliferation of cultured tendon fibroblasts derived from rat Achilles tendon was not directly affected by BPC 157 as evaluated by MTT assay19

  • in vitroBPC 157 significantly increased the survival of cells under H2O2 stress19

  • in vitroBPC 157 markedly increased the in vitro migration of tendon fibroblasts in a dose-dependent manner19

  • in vitroBPC 157 dose dependently accelerated the spreading of tendon fibroblasts on culture dishes19

  • in vitroBPC 157 induced F-actin formation in fibroblasts as detected by FITC-phalloidin staining19

  • in vitroBPC 157 dose dependently increased phosphorylation levels of FAK and paxillin while total protein amounts were unaltered19

  • in vitroBPC 157 promotes tendon fibroblast migration likely mediated by activation of the FAK-paxillin pathway19

  • in vitroBPC-157 interacts with the NO synthase (NOS) pathway, influencing both endothelial NOS (eNOS) and inducible NOS (iNOS) activity23

  • in vitroBPC-157 promotes angiogenesis through upregulation of vascular endothelial growth factor (VEGF) and its receptor VEGFR223

  • in vitroIn vitro studies using tendon fibroblasts have demonstrated that BPC-157 activates the FAK-paxillin signaling pathway23

  • in vitroBPC-157 enhances the expression of growth hormone receptors in tendon fibroblasts in a dose- and time-dependent manner23

  • in vitroBPC-157 interacts with EGF, FGF, and HGF in the context of gastrointestinal and musculoskeletal healing23

  • expert opinionBPC-157 is a pentadecapeptide isolated from human gastric juice12

  • expert opinionThere is a need to understand the precise healing mechanisms for BPC 157 to achieve clinical realisation16

  • expert opinionBPC 157 acts through different vasoactive pathways and systems including NO, VEGF, and FAK18

  • expert opinionBPC 157 leads to optimization of the vascular response followed by optimization of the healing process18

  • expert opinionBPC 157 affects endothelium damage, clotting, thrombosis, vasoconstriction, vasodilatation, vasculoneogenesis and edema formation18

  • expert opinionBPC-157 is a 15-amino acid synthetic peptide derived from a naturally occurring protein found in human gastric juice20

  • expert opinionBPC-157 triggers healing through multiple biological pathways including increased blood vessel formation, enhanced cell migration to injury sites, and amplified growth hormone receptor activity20

  • expert opinionBPC-157 consists of 15 amino acids arranged in sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val20

  • expert opinionParent compound exists naturally in human gastric juice as part of a much larger protein weighing approximately 40,000 daltons20

  • expert opinionBPC-157 weighs 1,419 daltons20

  • expert opinionBPC-157 contains four proline residues including an unusual triple-proline sequence giving it exceptional stability and resistance to breakdown by digestive enzymes20

  • expert opinionResearch has identified at least six distinct molecular mechanisms through which BPC-157 promotes tissue repair and regeneration20

  • expert opinionBPC-157 is not a naturally occurring bioactive peptide in the conventional sense21

  • expert opinion2014 review framed the peptide as acting in parallel with nitric oxide synthase modulators and preserving NO homeostasis across gastric, vascular, and wound-healing injury models21

  • expert opinionBPC 157 is a synthetic peptide derived from stomach acid protein22

  • expert opinionBPC-157 is derived from a larger protein known as Body Protection Compound, which is naturally present in human gastric juice23

  • expert opinionThe Akt-eNOS axis is a key signaling node through which BPC-157 promotes angiogenesis, and ERK1/2 signaling facilitates endothelial and muscle repair23

  • expert opinionBPC-157 is a peptide with regenerative properties26

  • theoreticalBPC-157 is a pentadecapeptide, a protein with 15 amino acids7

  • theoreticalBPC-157 is a wound-healing peptide that promotes angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation8

  • theoreticalBPC-157 acts on key pathways such as PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK to exert influence over tissue regeneration, inflammation resolution, and neuromuscular recovery8

  • theoreticalBPC-157 is a naturally occurring gastric peptide that promotes mucosal integrity and homeostasis11

  • theoreticalBPC 157 is a stable gastric pentadecapeptide17

  • theoreticalBPC-157 produces sustained pharmacodynamic effects over days to weeks despite short serum half-life27

  • theoreticalBPC-157 mechanism triggers downstream signalling cascades (VEGFR2 activation, fibroblast migration, angiogenesis) that persist well beyond direct peptide presence27

  • theoreticalBPC-157 metabolism involves proteolytic cleavage by plasma, hepatic and renal peptidases27

  • theoreticalBPC-157 activates VEGFR2 and FAK-paxillin pathways whose downstream effects unfold over days to weeks after initial receptor engagement27

Dosing

Based on 3 expert opinion findings and 1 theoretical finding.

  • expert opinionInformation regarding the indications, dosing, frequency, and duration of treatment remains unknown for BPC-1573

  • expert opinionStandard protocols suggest 0.25 to 0.5 mg daily via subcutaneous injection for general healing support20

  • expert opinionRoutes studied: Intraperitoneal, subcutaneous, intragastric, oral (in drinking water), topical23

  • theoreticalBPC 157 can be administered intraperitoneally, per-orally or locally17

How the body handles it

Based on 18 animal findings, 4 in vitro findings, 6 expert opinion findings and 6 theoretical findings.

  • animalElimination half-life (t 1/2) of prototype BPC157 was less than 30 min6

  • animalBPC157 showed linear pharmacokinetic characteristics in rats and beagle dogs at all doses6

  • animalMean absolute bioavailability of BPC157 following IM injection was approximately 14%–19% in rats6

  • animalMean absolute bioavailability of BPC157 following IM injection was approximately 45%–51% in beagle dogs6

  • animalMain excretory pathways of BPC157 involved urine and bile6

  • animal[3H]BPC157 was rapidly metabolized into a variety of small peptide fragments in vivo, thus forming single amino acids that entered normal amino acid metabolism and excretion pathways6

  • animalBPC-157 is metabolized in the liver, with a half-life of less than 30 minutes, and is cleared by the kidneys11

  • animalBPC157 can be stored at room temperature and is resistant to hydrolysis, enzyme digestion, and even gastric juice14

Show the remaining 26

  • animalThe elimination half-life (t1/2) of prototype BPC157 was less than 30 min in rats and beagle dogs14

  • animalBPC157 showed linear pharmacokinetic characteristics in rats and beagle dogs at all doses14

  • animalThe mean absolute bioavailability of BPC157 following IM injection was approximately 14%–19% in rats14

  • animalThe mean absolute bioavailability of BPC157 following IM injection was approximately 45%–51% in beagle dogs14

  • animalThe main excretory pathways of BPC157 involved urine and bile14

  • animal[3H]BPC157 was rapidly metabolized into a variety of small peptide fragments in vivo, thus forming single amino acids that entered normal amino acid metabolism and excretion pathways14

  • animalVery early in vivo research on pharmacokinetics indicates the possibility that BPC-157 may optimize endurance training, metabolism, recovery, and tissue repair25

  • animalSerum half-life estimate of 1-4 hours (IP administration) is a reasonable working assumption for rodent studies27

  • animalBPC-157 distributes broadly with notable accumulation in GI mucosa27

  • animalBPC-157 distributes to injury sites including tendon, ligament, and muscle27

  • in vitroBPC-157 is freely soluble in water of normal pH value7

  • in vitroBPC-157 is quite stable relative to other peptides by not degrading in stomach acid (ex vivo) for at least 24 hours7

  • in vitro36% of the intact peptide remaining after 60 minutes in plasma ex vivo7

  • in vitroA large amount of BPC-157 is registered as metabolites (79+/-2%) of the parent compound within 60 minutes when incubated in plasma ex vivo7

  • expert opinionThe effects of orally ingested BPC-157 are currently unknown7

  • expert opinionBPC-157 remains stable in gastric juice for over 24 hours20

  • expert opinionPlasma half-life under 30 minutes21

  • expert opinionNo published human pharmacokinetic data21

  • expert opinionBPC-157 is notable for its stability in gastric juice23

  • expert opinionHalf-life estimated <30 minutes (IM/IV); stable in gastric juice23

  • theoreticalBPC-157 has a relatively short serum half-life (estimated minutes to a few hours)27

  • theoreticalIP (intraperitoneal) administration provides rapid absorption through peritoneal surface with near-complete systemic delivery27

  • theoreticalIM (intramuscular) administration shows slower absorption than IP with sustained release from injection depot27

  • theoreticalSC (subcutaneous) administration is slower still and less characterised27

  • theoreticalOral BPC-157 shows variable absorption with some peptide reaching systemic circulation but at likely reduced bioavailability compared to parenteral routes27

  • theoreticalBPC-157 is likely cleared primarily through proteolytic degradation and subsequent clearance of amino acids and small fragments27

Safety and side effects

Based on 5 human trial findings, 5 human study findings, 5 animal findings, 14 expert opinion findings and 1 theoretical finding.

  • human trialIntravenous infusion of 10 mg BPC-157 in 250 cc normal saline over one hour resulted in no measurable effects on biomarkers of heart, liver, kidneys, thyroid, or blood glucose levels4

  • human trialIntravenous infusion of 20 mg BPC-157 in 250 cc normal saline over one hour resulted in no measurable effects on biomarkers of heart, liver, kidneys, thyroid, or blood glucose levels4

  • human trialBPC-157 peptide infusion was tolerated with no side effects reported in 2 healthy adults4

  • human trialIntravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults showed no adverse effects and was well-tolerated4

  • human trialNo adverse events were reported5

  • human studyNo adverse effects were reported in human pilot studies1

  • human studyHuman pilot studies suggest potential therapeutic value without reported major adverse effects2

  • human studyNo adverse effects were reported in the three human pilot studies9

Show the remaining 22

  • human studyNo adverse effects were reported in the three human pilot studies13

  • human studyBPC-157 is a stable gastric pentadecapeptide previously employed in ulcerative colitis and multiple sclerosis trials with no reported toxicity15

  • animalAnimal data indicate favorable safety and pharmacokinetics for BPC-1572

  • animalBPC 157 has a desirable safety profile with only a few side effects reported following its administration10

  • animalPreclinical safety studies showed no adverse effects across several organ systems11

  • animalBPC-157 has a desirable safety profile with only a few side effects reported following its administration12

  • animalBPC157 was well tolerated and did not demonstrate any serious toxic effects in mice, rats, rabbits, or dogs14

  • expert opinionWADA banned BPC-157 in 2022 under the S0 Unapproved Substances category1

  • expert opinionFDA classified BPC-157 as a Category 2 bulk drug in September 2023, barring its inclusion in compounded medications1

  • expert opinionThere are few studies reporting any adverse reactions to the administration of BPC 15716

  • expert opinionNo FDA-approved indication21

  • expert opinionClassified as a 503A Category 2 bulk drug substance since September 202321

  • expert opinionCannot be legally obtained through a licensed compounding pharmacy in the United States21

  • expert opinionThe effectiveness and safety of BPC 157 in humans remain unproven due to the lack of rigorous clinical trials22

  • expert opinionBPC 157 is unregulated and lacks FDA approval22

  • expert opinionBPC 157 is listed as a prohibited substance by the World Anti-Doping Agency22

  • expert opinionUSADA emphasizes BPC 157's unapproved status and the speculative nature of its benefits22

  • expert opinionBPC-157 has not received regulatory approval for therapeutic use in any jurisdiction23

  • expert opinionBPC-157 is classified as a prohibited substance by the World Anti-Doping Agency (WADA)23

  • expert opinionRigorous human safety data for BPC-157 are scarce24

  • expert opinionBPC-157 has potential for serious harm to patients24

  • theoreticalNo clinical safety data were found11

What people use it for

Based on 2 human trial findings, 1 human study finding, 8 animal findings and 8 expert opinion findings.

  • human trialBPC-157 is a possible treatment for interstitial cystitis5

  • human trialIntravesical BPC-157 injection helped patients with moderate to severe interstitial cystitis who did not respond to pentosan polysulfate treatment5

  • human studyIntra-articular injection of BPC-157 helps with multiple types of knee pain26

  • animalBPC-157 may be hepatoprotective1

  • animalBPC-157 may aid recovery from traumatic brain injury1

  • animalBPC-157 contributes to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue2

  • animalBPC-157 effects are particularly effective in poorly vascularized tissues such as tendons and myotendinous junctions9

  • animalBPC157 can promote the healing of wounds, ligament injuries, tendon injuries, and fractures14

Show the remaining 11

  • animalBPC157 exerts a significant protective effect on various tissues and organs, such as the esophagus, stomach, duodenum, colorectal mucosa, liver, pancreas, muscle, cornea, heart and nerves14

  • animalBPC-157 has practical applicability given alone with the same dose range and same equipotent routes of application regardless of injury tested15

  • animalBPC-157 therapy produces healing in gastrointestinal tract, tendon, ligament, muscle, bone, nerve, spinal cord, cornea, and blood vessels15

  • expert opinionBPC-157 has been used for years to treat partial muscle or tendon tears4

  • expert opinionBPC-157 is a synthetic peptide that is being investigated for its regenerative effects7

  • expert opinionBPC-157 lacks US Food and Drug Administration approval and its use is banned in professional sports11

  • expert opinionBPC 157 has potential as a therapy to conservatively treat or aid recovery in hypovascular and hypocellular soft tissues such as tendon and ligaments16

  • expert opinionBPC 157 use is not recommended due to significant uncertainties and risks22

  • expert opinionBPC-157 is marketed as an unapproved peptide compound direct to patients24

  • expert opinionBPC-157 is used in sports medicine for accelerated injury recovery24

  • expert opinionInjectable peptides may be used to enhance recovery and expedite return from injury in high-level athletes and bodybuilders25

Other findings

Based on 4 in vitro findings, 19 expert opinion findings and 2 theoretical findings.

  • in vitroBPC157 comprises 15 amino acids (Gly-Glu-Pro-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val)14

  • in vitroBPC157 has a molecular weight of 1419 Da14

  • in vitroBPC 157 is a pentadecapeptide composed of 15 amino acids19

  • in vitroBPC 157 is a partial sequence of body protection compound (BPC) discovered in and isolated from human gastric juice19

  • expert opinionBPC-157 is a synthetic pentadecapeptide originally isolated from gastric juice1

  • expert opinionBPC-157 was originally isolated from human gastric juice by Dr. Predrag Sikiric in 19931

  • expert opinionBPC-157 is a synthetic pentadecapeptide derived from gastric proteins2

  • expert opinionBPC-157 has inconsistent preparation standards2

Show the remaining 17

  • expert opinionBPC-157 faces regulatory restrictions2

  • expert opinionFew studies on humans have been published, with none on the intravenous use of BPC-157 in humans4

  • expert opinionBPC-157 is a synthetic pentadecapeptide originally isolated from gastric juice9

  • expert opinionRigorous, large-scale human trials are lacking9

  • expert opinionBPC-157 was temporarily banned by the World Anti-Doping Agency (WADA) in 202212

  • expert opinionBPC-157 is not currently listed as banned by the WADA12

  • expert opinionBPC-157 is a synthetic pentadecapeptide originally isolated from gastric juice13

  • expert opinionThe majority of studies investigating BPC 157 have been performed on small rodent models16

  • expert opinionFirst isolated and characterized in 1993 by researchers at the University of Zagreb, Croatia, led by Dr. Predrag Sikiric20

  • expert opinionBPC-157 is a synthetic 15-amino acid peptide21

  • expert opinionBPC-157 derived from partial sequence of a protein found in human gastric juice21

  • expert opinionFirst characterized in the early 1990s by Sikirić, Seiwerth, and colleagues21

  • expert opinionBPC-157 is a synthetic pentadecapeptide consisting of 15 amino acids (GEPPPGKPADDAGLV)23

  • expert opinionMolecular weight of 1419.53 g/mol23

  • expert opinionBPC-157 is unregulated and readily available for purchase over the internet25

  • theoreticalBPC 157 is a pentadecapeptide isolated from human gastric juice10

  • theoreticalBPC-157 is a 15 amino acid peptide of approximately 1419 Da27

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

Almost all evidence is preclinical; human data are minimal.

Multiple reviews (Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing | Current Reviews in Musculoskeletal Medicine | Springer Nature Link, From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management, Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing., Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review., Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians., Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions., Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?) agree that BPC-157's benefits are demonstrated mainly in animal/in vitro models, with only three small pilot human studies and no completed controlled efficacy trials. A 2025 systematic review (Superpower) documented zero completed controlled human efficacy trials.

Contested

Half-life estimates vary between sources.

Animal PK studies and most sources report elimination half-life under 30 minutes (Frontiers | Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs, Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs, Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.), while a theoretical UK review (BPC-157 Half-Life and Pharmacokinetics - Peptides Lab UK) estimates minutes to a few hours, with a 1–4 hour working estimate for IP administration in rodents.

Single source

Human efficacy figures come from single small, uncontrolled studies.

The knee-pain results (up to 16 patients, Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.; 12 patients, Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.) and the interstitial cystitis results (12 women, Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.) each derive from single small studies; Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. notes the knee case series had significant methodological flaws and no controls.

Limited evidence

Human intravenous safety data rest on only two participants.

The only intravenous human study (Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.) tested 10 mg and 20 mg infusions in just 2 healthy adults, limiting generalizability despite reporting no adverse effects.

Other

Preparation standards and product quality are inconsistent and unregulated.

A tier-1 review (From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management) notes inconsistent preparation standards and regulatory restrictions, and Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?/Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. note it is sold unregulated over the internet and directly to patients, raising quality concerns.

Single source

Anecdotal timelines and user outcomes come from vendor marketing.

Claims about improvement within 3–7 days, optimal benefits at 4–8 weeks, and a specific user's pain reduction from 7/10 to 2–3/10 come solely from a vendor profile (How BPC-157 Works: 6 Healing Mechanisms Explained (2026)) and are anecdotal.

Using it with other compounds

Check a stack
  • TB-500Complementary

    May be complementary

    BPC-157 and TB-500 drive tissue repair through entirely different molecular targets (VEGF/NO signalling vs. actin regulation), so they are frequently discussed as a complementary healing pair rather than a redundant one.

    Tier 3Largely anecdotal — commonly discussed

    Shares tissue repair · angiogenesis

  • IpamorelinComplementary

    No documented conflict

    BPC-157 upregulates the GH receptor and drives tissue repair through angiogenic/VEGFR2 and eNOS pathways, while ipamorelin raises circulating GH that can act on those upregulated receptors — a mechanistically complementary pairing often used anecdotally for recovery. Distinct mechanisms, shared repair/growth output.

    Tier 4Theoretical — not established
  • CJC-1295Same downstream effect

    Worth caution

    BPC-157 is reported to upregulate growth hormone receptor expression in tendon fibroblasts, sensitizing tissue to GH/IGF-1-driven repair. CJC-1295 raises systemic GH and IGF-1 from a different starting point (GHRH receptor). Together they may converge on the same anabolic/repair output — one increasing the signal (IGF-1), the other increasing receptor availability at the repair site.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanism material for BPC-157 lists 'Growth hormone receptor' as a target but provides no evidence it upregulates GH receptor expression in fibroblasts or sensitizes tissue to GH/IGF-1. The explanation asserts this without support from the provided description. While CJC-1295 clearly elevates GH/IGF-1 via GHRH receptor→cAMP/PKA, and BPC-157's pathways include growth factor induction (EGR-1) and tissue repair, the mechanisms do not explicitly establish convergence on GH/IGF-1 signaling as a shared downstream output. The proposed relationship requires an unsupported claim about BPC-157's effect on GH receptor expression to justify the same_downstream classification.
  • MOTS-cComplementary

    No documented conflict

    Both engage AMPK and HO-1/antioxidant (HMOX1) cytoprotective signaling. BPC-157 is oriented toward tissue repair and vascular integrity while MOTS-c is metabolic, so overlap is modest but the shared cytoprotective pathways make them compatible rather than conflicting.

    Tier 4Theoretical — not established
  • GHK-CuComplementary

    May be complementary

    Both peptides promote wound healing, collagen synthesis and angiogenesis through overlapping PI3K/Akt, mTOR, TGF-β and AMPK signaling, but via distinct entry points: BPC-157 through VEGFR2/eNOS and growth-factor induction, GHK-Cu through copper delivery, lysyl-oxidase-driven collagen/elastin crosslinking and Nrf2 antioxidant activation. They are frequently combined for skin/connective-tissue remodeling.

    Tier 4Theoretical — not established
  • KPVComplementary

    No documented conflict

    Both are studied for gut healing and inflammation. BPC-157 provides mucosal cytoprotection and microvascular repair, while KPV suppresses NF-kB and pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and protects the intestinal epithelial barrier. Different mechanisms converging on gut mucosal recovery, making them a plausible complementary GI pairing.

    Tier 4Theoretical — not established
  • HexarelinComplementary

    Worth caution

    Hexarelin shows GH-independent cardioprotective and anti-fibrotic effects (NLRP3/NF-κB and TGF-β suppression, PI3K/Akt survival signaling), while BPC-157 drives angiogenesis and tissue repair via VEGFR2/eNOS and overlapping PI3K/Akt–ERK pathways. Different upstream targets converging on tissue repair and cytoprotection make them potentially complementary for recovery contexts.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    While the explanation identifies overlapping downstream pathways (PI3K/Akt, ERK1/2) and both peptides have cytoprotective/tissue repair effects, the mechanism descriptions do not establish complementarity as a justified relationship type. The proposed relationship lacks specificity: it does not identify which shared dimensions actually constitute the complementarity, merely listing 'none' and then asserting convergence on 'tissue repair and cytoprotection' without mechanistic detail. Hexarelin's mechanisms emphasize GH axis stimulation, cardioprotection via inflammasome/NF-κB suppression, and anti-fibrosis via TGF-β suppression. BPC-157's mechanisms emphasize angiogenesis via VEGFR2/eNOS and wound healing via integrin-ECM remodeling and growth factor induction. The mechanism descriptions do not show how these distinct upstream actions (GHS-R1a vs. VEGFR2; ghrelin mimicry vs. gastric-juice-derived peptide) work synergistically or fill complementary roles in a defined therapeutic context. Complementarity requires explicit evidence of non-overlapping but coordinated mechanisms; the descriptions support only partial pathway overlap without demonstrating functional complementarity.
  • LL-37Complementary

    Worth caution

    Both promote angiogenesis and wound epithelialization, but LL-37 adds broad-spectrum antimicrobial and endotoxin-neutralizing activity that BPC-157 lacks. In a contaminated or infected wound context the two are complementary — LL-37 clears microbes/biofilm while BPC-157 drives vascular and connective-tissue repair. Note LL-37 has context-dependent pro-inflammatory effects, so monitoring is reasonable.

    Tier 4Theoretical — not established
  • AOD-9604Complementary

    No documented conflict

    Beyond fat loss, AOD-9604 has shown cartilage regeneration in an animal osteoarthritis model, an effect that overlaps with BPC-157's tissue-repair and collagen/fibroblast activity — complementary for joint recovery contexts (both preclinical).

    Tier 4Theoretical — not established

Safety and side effects

Safety and side effects

Animal safety studies report BPC-157 was well tolerated and did not demonstrate serious toxic effects in mice, rats, rabbits or dogs (src-4, src-15). Reviews report a desirable safety profile with only a few side effects reported, and preclinical studies showed no adverse effects across several organ systems, though one review notes no clinical safety data were found (src-1, src-6, src-16, src-17, src-18). An animal study reports it was previously employed in ulcerative colitis and multiple sclerosis trials with no reported toxicity, and that its LD1 was not achieved (src-20).

Human safety data are minimal. The three small pilot human studies reported no adverse effects (src-3, src-6, src-8, src-23); the intravesical interstitial cystitis study in 12 women reported no adverse events (src-30); and the intravenous study reported that 10 mg and up to 20 mg infusions were well tolerated with no side effects — but that study tested only 2 healthy adults, limiting generalizability (src-28).

Cautions

One review states rigorous human safety data for BPC-157 are scarce and that it has potential for serious harm to patients (src-26). One expert source states its effectiveness and safety in humans remain unproven due to lack of rigorous clinical trials, that it is unregulated and prohibited by WADA and flagged by USADA, and that its use is not recommended due to significant uncertainties and risks (src-13). Sources note it is sold unregulated over the internet and directly to patients, raising product quality concerns, and a tier-1 review notes inconsistent preparation standards (src-6, src-24, src-26). BPC-157 has no FDA-approved indication and, since September 2023, cannot be included in compounded medications in the U.S. (src-9).

Reconstitution and handling

Dosing

No dose has been established for this compound. BPC-157 has not received regulatory approval in any jurisdiction and has no FDA-approved indication (src-8, src-9, src-62), so the figures below are what sources report — not guidance. A review explicitly states that information regarding indications, dosing, frequency and duration of treatment for BPC-157 remains unknown (src-21).

  • A vendor profile suggests protocols of 0.25 to 0.5 mg daily via subcutaneous injection for general healing support (src-11).
  • Sources list routes studied for BPC-157 as intraperitoneal, subcutaneous, intragastric, oral (in drinking water), topical, per-oral and local administration (src-8, src-25).
  • In the human pilot studies, doses reported include intra-articular injections for knee pain (src-19), a single 10 mg intravesical treatment for interstitial cystitis (src-30), and intravenous infusions of 10 mg and up to 20 mg in 250 cc normal saline over one hour (src-28).
  • A theoretical review describes IP administration as offering rapid, near-complete systemic delivery, IM as slower with depot release, SC as slower still and less characterised, and oral as variable with likely reduced bioavailability (src-10).

Anecdotal timelines

A vendor profile reports anecdotal user experience that most users notice initial improvements within 3 to 7 days and optimal benefits over 4 to 8 weeks, including one user whose shoulder pain reportedly improved from 7/10 to 2–3/10 over 6 weeks at 0.25 mg twice daily subcutaneously (src-11). These timelines and outcomes come solely from vendor marketing and are anecdotal.

Preparation and stability

Sources report BPC-157 is freely soluble in water at normal pH, can be stored at room temperature, and is resistant to hydrolysis, enzyme digestion and gastric juice, remaining stable in gastric juice for over 24 hours (src-4, src-8, src-11, src-14). Preparation standards and product quality are described as inconsistent and unregulated, with the compound sold over the internet and directly to patients (src-6, src-24, src-26), raising quality concerns.

Sources

Ordered by evidence quality — the strongest first.

  1. Regeneration or Risk? A Narrative Review of BPC-157 for ...(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  2. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management(opens in a new tab)
    Tier 1Web · mdpi.com · 2026
  3. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  4. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  5. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  6. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  7. Research Breakdown on BPC-157 - Examine(opens in a new tab)
    Tier 2Web · examine.com
  8. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  9. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing | Current Reviews in Musculoskeletal Medicine | Springer Nature Link(opens in a new tab)
    Tier 2Web · link.springer.com · 2025
  10. Multifunctionality and Possible Medical Application of the ...(opens in a new tab)
    Tier 2Web · mdpi.com · 2025
  11. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  12. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  13. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  14. Frontiers | Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs(opens in a new tab)
    Tier 2Web · frontiersin.org · 2022
  15. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  16. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2019
  17. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2018
  18. BPC 157 and blood vessels.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2014
  19. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2011
  20. How BPC-157 Works: 6 Healing Mechanisms Explained (2026)(opens in a new tab)
    Tier 3Web · redfoxpeptides.is
  21. Superpower(opens in a new tab)
    Tier 3Web · superpower.com
  22. What Science ACTUALLY Says About BPC 157 Benefits(opens in a new tab)
    Tier 3Web · youtube.com
  23. BPC-157 (Body Protection Compound-157): Research Evidence & Safety Profile | PeptideInsight(opens in a new tab)
    Tier 3Web · peptideinsight.com · 2026
  24. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  25. Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  26. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  27. BPC-157 Half-Life and Pharmacokinetics - Peptides Lab UK(opens in a new tab)
    Tier 4Web · peptideslabuk.com
  28. Pharmacokinetics, distribution, metabolism, and excretion of ...(opens in a new tab)
    Tier 4Web · pmc.ncbi.nlm.nih.gov
  29. Regeneration or Risk? A Narrative Review of BPC-157 for ...(opens in a new tab)
    Tier 4Web · pmc.ncbi.nlm.nih.gov
  30. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers(opens in a new tab)
    Tier 4Web · pubmed.ncbi.nlm.nih.gov · 2026